Skip to main
CANF

CANF Stock Forecast & Price Target

CANF Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Can Fite Biopharma is a clinical-stage biopharmaceutical company with a pipeline of potentially promising drugs targeting the A3 adenosine receptor. Key drivers of this positive outlook include a strong clinical pipeline, encouraging Phase 2a findings, planned Phase 2b combination study in pancreatic cancer, and projected future revenues through 2032. However, potential risks to the thesis include commercial, regulatory, and clinical concerns. Based on a risk analysis and projected financials, we estimate a 12-month price target of $5.00 per ADS for Can Fite Biopharma.

Bears say

Can Fite Biopharma is a clinical-stage biopharmaceutical company with a negative outlook due to several factors. Despite showing favorable safety profiles and clinical activity in Phase 2a trials for pancreatic cancer, the company's drug candidate Piclidenoson has not demonstrated significant efficacy or attracted industry attention, indicating potential issues with its effectiveness. Additionally, while a planned Phase 2b study may improve visibility, the company's focus on a combination immunotherapy strategy in this field is an unproven approach, and the limited treatment options available for pancreatic cancer could make it difficult for the company to stand out in this competitive market.

CANF has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Can-Fite BioPharma Ltd. (CANF) Forecast

Analysts have given CANF a Strong Buy based on their latest research and market trends.

According to 2 analysts, CANF has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Can-Fite BioPharma Ltd. (CANF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.